JP6295348B2 - 抗ウイルス化合物を調製するためのプロセス - Google Patents
抗ウイルス化合物を調製するためのプロセス Download PDFInfo
- Publication number
- JP6295348B2 JP6295348B2 JP2016572416A JP2016572416A JP6295348B2 JP 6295348 B2 JP6295348 B2 JP 6295348B2 JP 2016572416 A JP2016572416 A JP 2016572416A JP 2016572416 A JP2016572416 A JP 2016572416A JP 6295348 B2 JP6295348 B2 JP 6295348B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- reaction conditions
- acid
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(CCc(c1c2)cc-3c2OCc2c-3ccc(C(C*)=O)c2)C1=O Chemical compound CC(CCc(c1c2)cc-3c2OCc2c-3ccc(C(C*)=O)c2)C1=O 0.000 description 8
- LVXGLNJKOZUPRW-UHFFFAOYSA-N C#Cc1ccc2-c(cc(CCCC3=O)c3c3)c3OCc2c1 Chemical compound C#Cc1ccc2-c(cc(CCCC3=O)c3c3)c3OCc2c1 LVXGLNJKOZUPRW-UHFFFAOYSA-N 0.000 description 1
- DUMCZOFJFQAKSR-UHFFFAOYSA-N C=Cc1ccc2-c(cc(CCCC3=O)c3c3)c3OCc2c1 Chemical compound C=Cc1ccc2-c(cc(CCCC3=O)c3c3)c3OCc2c1 DUMCZOFJFQAKSR-UHFFFAOYSA-N 0.000 description 1
- BEXBCJDNMFRAGD-UWVGGRQHSA-N CC(C)[C@@H](C(N1[C@@H](C)CCC1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N1[C@@H](C)CCC1)=O)NC(OC)=O BEXBCJDNMFRAGD-UWVGGRQHSA-N 0.000 description 1
- AYAFFHCFJMWXMH-UMNHJUIQSA-N CC(C)[C@@H](C(N1[C@@H](C)CC[C@H]1C)=O)NC(C=O)=O Chemical compound CC(C)[C@@H](C(N1[C@@H](C)CC[C@H]1C)=O)NC(C=O)=O AYAFFHCFJMWXMH-UMNHJUIQSA-N 0.000 description 1
- HSXZWLFYDVZTOT-AXFHLTTASA-N CC(C)[C@@H](C(N1[C@@H](C)CC[C@H]1C)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N1[C@@H](C)CC[C@H]1C)=O)NC(OC)=O HSXZWLFYDVZTOT-AXFHLTTASA-N 0.000 description 1
- CEFVHPDFGLDQKU-YFKPBYRVSA-N CC(C)[C@@H](C(O)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(O)=O)NC(OC)=O CEFVHPDFGLDQKU-YFKPBYRVSA-N 0.000 description 1
- NVSLOKHCHIFJDR-UHFFFAOYSA-N O=C(CBr)c1ccc2-c(cc(CCC(C3=O)Br)c3c3)c3OCc2c1 Chemical compound O=C(CBr)c1ccc2-c(cc(CCC(C3=O)Br)c3c3)c3OCc2c1 NVSLOKHCHIFJDR-UHFFFAOYSA-N 0.000 description 1
- LGFSAJZSDNYVCW-UHFFFAOYSA-N Oc1ccc(CCCC2=O)c2c1 Chemical compound Oc1ccc(CCCC2=O)c2c1 LGFSAJZSDNYVCW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462010813P | 2014-06-11 | 2014-06-11 | |
| US62/010,813 | 2014-06-11 | ||
| PCT/US2015/034655 WO2015191437A1 (en) | 2014-06-11 | 2015-06-08 | Processes for preparing antiviral compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018001740A Division JP2018052985A (ja) | 2014-06-11 | 2018-01-10 | 抗ウイルス化合物を調製するためのプロセス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517541A JP2017517541A (ja) | 2017-06-29 |
| JP6295348B2 true JP6295348B2 (ja) | 2018-03-14 |
Family
ID=53783899
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572416A Active JP6295348B2 (ja) | 2014-06-11 | 2015-06-08 | 抗ウイルス化合物を調製するためのプロセス |
| JP2018001740A Withdrawn JP2018052985A (ja) | 2014-06-11 | 2018-01-10 | 抗ウイルス化合物を調製するためのプロセス |
| JP2019137834A Active JP6954959B2 (ja) | 2014-06-11 | 2019-07-26 | 抗ウイルス化合物を調製するためのプロセス |
| JP2021133343A Withdrawn JP2021178872A (ja) | 2014-06-11 | 2021-08-18 | 抗ウイルス化合物を調製するためのプロセス |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018001740A Withdrawn JP2018052985A (ja) | 2014-06-11 | 2018-01-10 | 抗ウイルス化合物を調製するためのプロセス |
| JP2019137834A Active JP6954959B2 (ja) | 2014-06-11 | 2019-07-26 | 抗ウイルス化合物を調製するためのプロセス |
| JP2021133343A Withdrawn JP2021178872A (ja) | 2014-06-11 | 2021-08-18 | 抗ウイルス化合物を調製するためのプロセス |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9670187B2 (enExample) |
| EP (1) | EP3154984B1 (enExample) |
| JP (4) | JP6295348B2 (enExample) |
| KR (2) | KR20180114253A (enExample) |
| CN (1) | CN106488920A (enExample) |
| AR (1) | AR105050A1 (enExample) |
| AU (3) | AU2015274967B2 (enExample) |
| BR (1) | BR112016028773B1 (enExample) |
| CA (1) | CA2951138C (enExample) |
| EA (1) | EA201692219A1 (enExample) |
| ES (1) | ES2690868T3 (enExample) |
| IL (1) | IL248960A0 (enExample) |
| MX (1) | MX2016016297A (enExample) |
| NZ (1) | NZ726356A (enExample) |
| PT (1) | PT3154984T (enExample) |
| SG (1) | SG11201609828SA (enExample) |
| TW (2) | TWI679203B (enExample) |
| WO (1) | WO2015191437A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2358979C2 (ru) | 2003-05-30 | 2009-06-20 | Фармассет, Инк. | Модифицированные фторированные аналоги нуклеозида |
| KR101835474B1 (ko) | 2010-11-17 | 2018-03-08 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| US20130164260A1 (en) | 2011-11-16 | 2013-06-27 | Gilead Sciences, Inc. | Antiviral compounds |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| TWI679203B (zh) * | 2014-06-11 | 2019-12-11 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| US10487067B2 (en) * | 2015-10-08 | 2019-11-26 | Mylan Laboratories Limited | Process for the preparation of velpatasvir |
| WO2017112531A1 (en) * | 2015-12-21 | 2017-06-29 | Merck Sharp & Dohme Corp. | Silane-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| CN105712969B (zh) * | 2016-01-27 | 2018-07-27 | 杭州科巢生物科技有限公司 | 维帕他韦中间体的合成方法 |
| CN105732765B (zh) * | 2016-02-01 | 2019-07-26 | 杭州科巢生物科技有限公司 | 丙肝药物维帕他韦的新合成方法 |
| CN105732563B (zh) * | 2016-03-23 | 2018-08-28 | 江苏苏利精细化工股份有限公司 | 一种合成9-溴-3-(2-溴乙酰基)-10，11-二氢-5H-二苯并[c,g]色烯-8(9h)-酮的新方法 |
| WO2017191546A1 (en) * | 2016-05-05 | 2017-11-09 | Laurus Labs Private Ltd. | Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors |
| WO2017195894A1 (ja) * | 2016-05-13 | 2017-11-16 | 日産化学工業株式会社 | ２－アセチルピリジン化合物の製造方法 |
| CN106220639A (zh) * | 2016-07-22 | 2016-12-14 | 上海众强药业有限公司 | 一种维帕他韦中间体新晶型 |
| CN107573380B (zh) * | 2016-11-30 | 2020-06-02 | 上海博志研新药物技术有限公司 | 维帕他韦中间体、制备方法及应用 |
| CN106831737B (zh) * | 2017-02-27 | 2020-03-17 | 上海众强药业有限公司 | 维帕他韦及其衍生物的制备 |
| CN107629029A (zh) * | 2017-09-19 | 2018-01-26 | 安徽省诚联医药科技有限公司 | 维帕他韦中间体的制备方法 |
| CN107501229A (zh) * | 2017-09-27 | 2017-12-22 | 上海泓博智源医药股份有限公司 | 一种维帕他韦中间体的制备方法 |
| CN107987125A (zh) * | 2017-11-23 | 2018-05-04 | 爱斯特（成都）生物制药股份有限公司 | 一种缬氨酸衍生物的制备方法 |
| CN108218755A (zh) * | 2018-01-18 | 2018-06-29 | 上海仁实医药科技有限公司 | 一种N-Boc-4-氧代-L-脯氨酸叔丁酯的合成工艺 |
| CN110835353B (zh) * | 2018-08-15 | 2022-08-19 | 上海茂晟康慧科技有限公司 | 一种艾日布林中间体er804698的合成方法 |
| CN109265431B (zh) * | 2018-10-09 | 2020-05-26 | 江苏苏利精细化工股份有限公司 | 3-乙酰基-10，11-二氢-5h-二苯并[c,g]色烯-8（9h）-酮合成工艺 |
| TWI878337B (zh) * | 2019-08-19 | 2025-04-01 | 美商富曼西公司 | 用於製備3-鹵代-4,5-二氫-1h-吡唑的羧酸衍生物的方法 |
| IT201900018491A1 (it) * | 2019-10-10 | 2021-04-10 | Dr Schaer S P A | Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere |
| IT201900018488A1 (it) * | 2019-10-10 | 2021-04-10 | Dr Schaer S P A | Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere |
| CN111018870B (zh) * | 2019-11-29 | 2021-07-23 | 南京正济医药研究有限公司 | 一种维帕他韦中间体的制备方法 |
| CN112275146B (zh) * | 2020-09-01 | 2021-08-20 | 中国科学院山西煤炭化学研究所 | 一种经磷酸处理的Tröger`s Base聚合物气体分离膜及其制备方法和应用 |
| CN116462627A (zh) * | 2023-04-19 | 2023-07-21 | 南京优氟医药科技有限公司 | 一种3-溴代哌啶-2,6-二酮的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2473056A4 (en) * | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| WO2011066241A1 (en) * | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| KR101835474B1 (ko) | 2010-11-17 | 2018-03-08 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| US20130164260A1 (en) | 2011-11-16 | 2013-06-27 | Gilead Sciences, Inc. | Antiviral compounds |
| PE20142462A1 (es) * | 2012-02-13 | 2015-02-01 | Presidio Pharmaceuticals Inc | Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos |
| US20130309196A1 (en) * | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9056860B2 (en) * | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| TWI679203B (zh) | 2014-06-11 | 2019-12-11 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
-
2015
- 2015-05-28 TW TW104117181A patent/TWI679203B/zh active
- 2015-05-28 TW TW108139659A patent/TW202014413A/zh unknown
- 2015-06-08 PT PT15747596T patent/PT3154984T/pt unknown
- 2015-06-08 NZ NZ726356A patent/NZ726356A/en not_active IP Right Cessation
- 2015-06-08 JP JP2016572416A patent/JP6295348B2/ja active Active
- 2015-06-08 EA EA201692219A patent/EA201692219A1/ru unknown
- 2015-06-08 EP EP15747596.3A patent/EP3154984B1/en active Active
- 2015-06-08 AU AU2015274967A patent/AU2015274967B2/en active Active
- 2015-06-08 SG SG11201609828SA patent/SG11201609828SA/en unknown
- 2015-06-08 WO PCT/US2015/034655 patent/WO2015191437A1/en not_active Ceased
- 2015-06-08 KR KR1020187029248A patent/KR20180114253A/ko not_active Ceased
- 2015-06-08 CN CN201580031459.0A patent/CN106488920A/zh active Pending
- 2015-06-08 MX MX2016016297A patent/MX2016016297A/es unknown
- 2015-06-08 US US14/733,139 patent/US9670187B2/en active Active
- 2015-06-08 BR BR112016028773-8A patent/BR112016028773B1/pt active IP Right Grant
- 2015-06-08 KR KR1020177000461A patent/KR101908642B1/ko active Active
- 2015-06-08 ES ES15747596.3T patent/ES2690868T3/es active Active
- 2015-06-08 CA CA2951138A patent/CA2951138C/en active Active
- 2015-06-10 AR ARP150101834A patent/AR105050A1/es unknown
-
2016
- 2016-11-14 IL IL248960A patent/IL248960A0/en unknown
-
2017
- 2017-04-28 US US15/582,224 patent/US9890134B2/en active Active
- 2017-12-19 US US15/847,803 patent/US20180179175A1/en not_active Abandoned
-
2018
- 2018-01-10 JP JP2018001740A patent/JP2018052985A/ja not_active Withdrawn
- 2018-07-05 AU AU2018204886A patent/AU2018204886B2/en active Active
-
2019
- 2019-05-06 US US16/404,550 patent/US10584109B2/en active Active
- 2019-07-26 JP JP2019137834A patent/JP6954959B2/ja active Active
-
2020
- 2020-01-16 US US16/744,576 patent/US11192875B2/en active Active
- 2020-11-05 AU AU2020264335A patent/AU2020264335B2/en active Active
-
2021
- 2021-08-18 JP JP2021133343A patent/JP2021178872A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6954959B2 (ja) | 抗ウイルス化合物を調製するためのプロセス | |
| AU2015369668B2 (en) | Processes for preparing ASK1 inhibitors | |
| TWI671292B (zh) | 抗病毒化合物之合成 | |
| AU2013271772A1 (en) | Synthesis of antiviral compound | |
| HK1225388A1 (zh) | 通过环化2-(氨基乙氧基)苯甲酸衍生物制备3，4-二氢-1，4-苯并氧氮杂环庚三烯-5(2h)-酮衍生物 | |
| HK1236198B (en) | Processes for preparing antiviral compounds | |
| HK1236198A1 (en) | Processes for preparing antiviral compounds | |
| HK1234751A1 (en) | Processes for preparing antiviral compounds | |
| HK40095381A (en) | Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide | |
| HK40022676B (en) | Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170111 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161214 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171011 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171012 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180110 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180122 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180219 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6295348 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |